In a groundbreaking study published in npj Vaccines, researchers from The University of Tokyo and Shionogi & Co., Ltd. have unveiled a novel understanding of how squalene-based adjuvants elicit immune protection while also causing reactogenicity, such as local swelling and fever. This research challenges the long-held assumption that these two effects are inherently linked by revealing distinct cellular and molecular pathways underpinning each response. These insights pave the way for next-generation vaccine formulations that can maximize efficacy while minimizing adverse side effects.
Adjuvants serve as indispensable components in many modern vaccines, functioning to enhance immunogenicity by stimulating the immune system. Squalene-based adjuvants, renowned for their potent immunostimulatory capabilities, have been widely used in influenza vaccines and more recently in various other vaccine platforms. Yet, their use has been accompanied by concerns over reactogenicity—the inflammatory side effects manifesting at the injection site and systemically. Historically, efforts to improve adjuvants have been hindered by an assumed biological coupling of protective immunity and inflammatory side effects, complicating attempts to selectively optimize one without compromising the other.
The research team, led by Professor Ken J. Ishii at the Institute of Medical Science, University of Tokyo, systematically dissected the immunological pathways activated by squalene-based adjuvants through an integrative approach combining in vivo mouse models with in vitro human immune cell analyses. Leveraging advanced techniques such as RNA sequencing and multiparametric flow cytometry, they interrogated the early immune responses triggered post-vaccination. This multi-layered strategy allowed them to pinpoint specific cytokine signaling cascades and cell-type-specific effects responsible for either beneficial or adverse vaccine outcomes.
Central to their findings is the delineation of the interleukin-1 (IL-1) family’s dual roles mediated by its isoforms IL-1β and IL-1α. IL-1β emerged as the pivotal cytokine orchestrating vaccine efficacy; it activates CD11c-positive dendritic cells via the IL-1 receptor and the adaptor protein MyD88 to drive robust antibody production. This mechanism underscores how IL-1β-dependent signaling promotes antigen presentation and adaptive immune priming critical for protective immunity. On the other hand, IL-1α—predominantly produced by eosinophils—was implicated as the key mediator of localized inflammation causing injection site swelling, a major facet of reactogenicity.
Interestingly, systemic reactogenic effects, particularly fever, were shown to be governed by a separate downstream pathway activated by IL-1β. This route involves the induction of interleukin-6 (IL-6) and cyclooxygenase-2 (COX2), which are well-known effectors of the febrile response. This triad of cytokines and enzymes highlights a finely-tuned network where spatially and temporally distinct immune signals coordinate differential outcomes—protective immunity versus inflammatory discomfort. These nuanced insights shatter the simplistic notion that immune activation and adverse reactions are inseparable phenomena.
The study also unveiled the critical role of α-tocopherol, a form of vitamin E and an essential component in certain squalene adjuvant formulations such as AS03. Removal of α-tocopherol from the adjuvant substantially diminished both IL-1β-mediated immune activation and IL-1α-driven reactogenicity. This suggests that α-tocopherol potentiates signaling pathways responsible for both beneficial and adverse responses. Consequently, α-tocopherol represents a mechanistic fulcrum that could be strategically modulated to tune vaccine outcomes, providing a tangible target for adjuvant refinement.
Importantly, the investigators validated these phenomena not only in murine systems but also using human immune cells, suggesting translational relevance. Human dendritic cells and eosinophils exhibited similar cytokine profiles and functional responses when exposed to squalene adjuvants, reinforcing the potential for clinical applications. This cross-species conservation bolsters the feasibility of leveraging these findings to engineer safer, more effective vaccines for human use globally.
The implications of this work extend profoundly into future vaccine development strategies. By discriminating the immune pathways governing immunogenicity from those causing reactogenicity, vaccine scientists can now explore avenues to uncouple these effects. For instance, selectively targeting IL-1β signaling pathways in dendritic cells could amplify antigen-specific responses without overstimulating eosinophil-derived IL-1α or systemic IL-6/COX2 pathways implicated in inflammation and fever. This tailored modulation could revolutionize adjuvant design, yielding formulations that maintain strong, durable protection with minimized side effects.
Moreover, this research offers a compelling framework for improving public perception and acceptance of vaccines. Reactogenicity often deters individuals from vaccination, fueling vaccine hesitancy. By delivering vaccines that elicit fewer adverse reactions without sacrificing effectiveness, public confidence could be significantly enhanced, thereby improving vaccination coverage and, ultimately, population health outcomes. The prospect is especially vital as the world continues to grapple with emerging infectious threats requiring rapid and widespread immunization.
From a mechanistic standpoint, the study enriches our fundamental understanding of immune regulation. It underscores the sophisticated division of labor between cytokine isoforms and immune cell subsets in balancing protection and pathology. This knowledge resonates beyond vaccinology, offering insights into inflammatory and autoimmune conditions where IL-1 family cytokines are key players. The work may inspire novel therapeutic approaches that harness or mitigate specific IL-1 signaling pathways.
Technologically, the integration of state-of-the-art genomic profiling with classical immunological assays exemplifies the cutting-edge methodology required to unravel complex immune networks. The research highlights the value of combining murine in vivo models with human cell-based assays to bridge experimental findings to clinical practice. Such multidisciplinary strategies will invariably accelerate vaccine innovation and immunotherapy development going forward.
In summary, Professor Ishii and colleagues have charted a new course in vaccine immunology by revealing that distinct IL-1 isoforms and their cellular sources distinctly govern squalene adjuvant efficacy and reactogenicity. This paradigm shift offers unprecedented opportunities to fine-tune vaccine formulations, optimizing safety and immunogenicity in tandem. As the global community seeks ever more sophisticated immunization tools, these findings represent a vital step toward next-generation vaccines that are not only powerful but also comfortably tolerated by recipients.
With persistent efforts, the delineation of such immune pathways may enable customized adjuvant platforms designed for specific populations or diseases, marking a new era of precision vaccinology. Enhanced vaccine safety profiles could also expedite approval processes and broaden acceptance, especially in vulnerable or vaccine-nervous cohorts. Ultimately, this research underscores the promise of molecularly informed vaccine design in addressing both longstanding and emerging public health challenges.
As vaccinology evolves into a more precise science, mechanistic insights like those demonstrated in this study provide a fulcrum for innovation. By untangling the intricate crosstalk among cytokines, cell types, and signaling pathways induced by adjuvants, scientists can now envisage vaccines that not only protect but do so with minimal discomfort—a game changer in global immunization campaigns. This landmark advancement heralds a brighter future for vaccine development and infectious disease prevention worldwide.
Subject of Research: Animals
Article Title: IL-1 delineates squalene-based adjuvant efficacy and reactogenicity in a cell-type-specific manner
News Publication Date: 30-Mar-2026
Web References:
http://dx.doi.org/10.1038/s41541-026-01420-0
References:
Yoshioka, Y., Nishinaka-Yoshioka, A., Kobiyama, K., Hayashi, T., Kidani, Y., Yanagida, Y., Kasahara, J., Tsujii, K., Asaoka, Y., Kuroda, N., Kugimiya, A., Osawa, H., Yoshimura, A., Onishi, M., Nakagawa, T., Ishida, S., Omoto, S., Nagira, M., Coban, C., & Ishii, K. J. (2026). IL-1 delineates squalene-based adjuvant efficacy and reactogenicity in a cell-type-specific manner. npj Vaccines. https://doi.org/10.1038/s41541-026-01420-0
Image Credits: Prof. Ken J. Ishii, The University of Tokyo, Japan
Keywords: Vaccine research, vaccine development, squalene adjuvants, IL-1β, IL-1α, reactogenicity, immunogenicity, cytokines, vaccine safety, α-tocopherol, dendritic cells, eosinophils
